294 related articles for article (PubMed ID: 30423165)
1. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.
Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG; Camm AJ
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):70-79. PubMed ID: 30423165
[TBL] [Abstract][Full Text] [Related]
2. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG
Europace; 2019 Mar; 21(3):421-427. PubMed ID: 30052894
[TBL] [Abstract][Full Text] [Related]
3. Global Prospective Safety Analysis of Rivaroxaban.
Kirchhof P; Radaideh G; Kim YH; Lanas F; Haas S; Amarenco P; Turpie AGG; Bach M; Lambelet M; Hess S; Camm AJ;
J Am Coll Cardiol; 2018 Jul; 72(2):141-153. PubMed ID: 29976287
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.
Kitazono T; Ikeda T; Ogawa S; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Cavaliere M; Hayashi Y; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
Heart Vessels; 2020 Mar; 35(3):399-408. PubMed ID: 31492970
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
6. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
[TBL] [Abstract][Full Text] [Related]
7. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
[TBL] [Abstract][Full Text] [Related]
8. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Iwashiro S; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Thromb Thrombolysis; 2019 Nov; 48(4):653-660. PubMed ID: 31432451
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
[TBL] [Abstract][Full Text] [Related]
10. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
13. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Kuhls S; van Eickels M; Turpie AG;
Eur Heart J; 2016 Apr; 37(14):1145-53. PubMed ID: 26330425
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.
Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH
Europace; 2023 Oct; 25(10):. PubMed ID: 37738425
[TBL] [Abstract][Full Text] [Related]
15. Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.
Kirchhof P; Haas S; Amarenco P; Hess S; Lambelet M; van Eickels M; Turpie AGG; Camm AJ;
J Am Heart Assoc; 2020 Mar; 9(5):e009530. PubMed ID: 32079476
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
18. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Vimalesvaran K; Dockrill SJ; Gorog DA
Vasc Health Risk Manag; 2018; 14():13-21. PubMed ID: 29391805
[TBL] [Abstract][Full Text] [Related]
19. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
20. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.
Tamayo S; Frank Peacock W; Patel M; Sicignano N; Hopf KP; Fields LE; Sarich T; Wu S; Yannicelli D; Yuan Z
Clin Cardiol; 2015 Feb; 38(2):63-8. PubMed ID: 25588595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
